Cartesian Therapeutics, INC Form 4 insider transactions

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, reported the acquisition and disposal of company stock and stock options on November 14th and 15th, 2024.

Director Murat Kalayoglu reports a transaction involving the conversion of Series A Non-Voting Convertible Preferred Stock into common stock through a trust.

Elizabeth Hoge, a director and 10% owner of Cartesian Therapeutics, converted a portion of Series A Non-Voting Convertible Preferred Stock into common stock on October 11, 2024.

Timothy Springer, a Director and 10% owner of Cartesian Therapeutics, has significantly increased his holdings of common stock through a series of transactions between October 2nd and October 4th, 2024.

Director and 10% owner Timothy Springer reports the conversion of Series B Preferred Stock to Common Stock in Cartesian Therapeutics.

Director Timothy A. Springer reports purchasing 8,016 shares of Cartesian Therapeutics (RNAC) at an average price of $12.7205 on August 12, 2024.

Director Timothy C. Barabe recently purchased 7,500 shares of Cartesian Therapeutics (RNAC) at $12.70 per share, increasing his total holdings.

Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc., filed a Form 4 disclosing transactions involving Series B Non-Voting Convertible Preferred Stock and Common Stock.

Director Kemal Malik reports acquisition of common stock and stock options in Cartesian Therapeutics (RNAC) on July 1, 2024.

Director Michael Singer reports the conversion of Series A Preferred Stock into common stock and the impact of a 1-for-30 reverse stock split at Cartesian Therapeutics.

Murat Kalayoglu, a director and 10% owner of Cartesian Therapeutics, reports the conversion of Series A Preferred Stock into common stock and a 1-for-30 reverse stock split.

Timothy Springer, a director and 10% owner of Cartesian Therapeutics, reports changes in beneficial ownership due to a reverse stock split and conversion of Series A Preferred Stock.

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, reports exercising stock options and converting preferred stock to common stock following a 1-for-30 reverse stock split.

Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, reports adjustments to his stock options and common stock holdings following a reverse stock split and the conversion of Series A Preferred Stock.

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, reports exercising stock options and converting preferred stock to common stock following a reverse stock split.

Elizabeth Hoge, a director and 10% owner of Cartesian Therapeutics, reported the conversion of Series A Preferred Stock into Common Stock following stockholder approval.

Director Timothy Springer reports several purchases of Cartesian Therapeutics (RNAC) common stock made indirectly through his wife between January and March 2024, along with holdings through TAS Partners LLC.

Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc., reports acquiring shares through the exercise of a warrant.

Director and 10% owner Timothy A. Springer reports purchasing 19,044 shares of Cartesian Therapeutics at an average price of $0.5985 on March 18, 2024.

Director Timothy Springer reports purchasing additional shares of Cartesian Therapeutics (RNAC) on March 14 and 15, 2024.